245 related articles for article (PubMed ID: 33581579)
1. PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.
Wu L; Cai S; Deng Y; Zhang Z; Zhou X; Su Y; Xu D
Int Immunopharmacol; 2021 May; 94():107443. PubMed ID: 33581579
[TBL] [Abstract][Full Text] [Related]
2. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway.
Tsai TF; Lin JF; Lin YC; Chou KY; Chen HE; Ho CY; Chen PC; Hwang TI
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31341011
[TBL] [Abstract][Full Text] [Related]
4. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
[TBL] [Abstract][Full Text] [Related]
5. CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer.
Zhang C; Li Z; Xu L; Che X; Wen T; Fan Y; Li C; Wang S; Cheng Y; Wang X; Qu X; Liu Y
BMC Cancer; 2018 Apr; 18(1):462. PubMed ID: 29690901
[TBL] [Abstract][Full Text] [Related]
6. DJ-1 is involved in the multidrug resistance of SGC7901 gastric cancer cells through PTEN/PI3K/Akt/Nrf2 pathway.
Qiu L; Ma Z; Li X; Deng Y; Duan G; Zhao LE; Xu X; Xiao L; Liu H; Zhu Z; Chen H
Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(11):1202-1214. PubMed ID: 33079995
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
[TBL] [Abstract][Full Text] [Related]
8. HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma.
Zhang ZS; Yang RH; Yao X; Cheng YY; Shi HX; Yao CY; Gao ZX; Qi DF; Zhang WK; Dou YY; Guo J; Hu MW; Zhao H; Fang D
Cell Biol Int; 2021 Dec; 45(12):2521-2533. PubMed ID: 34486197
[TBL] [Abstract][Full Text] [Related]
9. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
10. Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells.
Yan F; Pang J; Peng Y; Molina JR; Yang P; Liu S
PLoS One; 2016; 11(9):e0162925. PubMed ID: 27610620
[TBL] [Abstract][Full Text] [Related]
11. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells.
Gao L; Guo Q; Li X; Yang X; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Xi T; Zheng L
EBioMedicine; 2019 Mar; 41():395-407. PubMed ID: 30803931
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Status in Gastric Cancers, Association with the Transcriptional, Growth Factors, AKT/mTOR Components Change, and Autophagy Initiation.
Spirina L; Avgustinovich A; Afanas'ev S; Volkov M; Dobrodeev A; Cheremisina O; Kostromitsky D
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681840
[TBL] [Abstract][Full Text] [Related]
13. Poncirin downregulates ATP-binding cassette transporters to enhance cisplatin sensitivity in cisplatin-resistant osteosarcoma cells.
Zhao L; Zhang W; Zhang F
Phytother Res; 2021 Jan; 35(1):278-288. PubMed ID: 32779800
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R
Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058
[TBL] [Abstract][Full Text] [Related]
16. Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-κB pathway.
Sui H; Pan SF; Feng Y; Jin BH; Liu X; Zhou LH; Hou FG; Wang WH; Fu XL; Han ZF; Ren JL; Shi XL; Zhu HR; Li Q
BMC Complement Altern Med; 2014 Aug; 14():279. PubMed ID: 25085593
[TBL] [Abstract][Full Text] [Related]
17. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
[TBL] [Abstract][Full Text] [Related]
18. Role of integrin-linked kinase in multi-drug resistance of human gastric carcinoma SGC7901/DDP cells.
Song W; Jiang R; Zhao CM
Asian Pac J Cancer Prev; 2012; 13(11):5619-25. PubMed ID: 23317227
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
Zhang X; Zeng Y; Qu Q; Zhu J; Liu Z; Ning W; Zeng H; Zhang N; Du W; Chen C; Huang JA
Int J Clin Oncol; 2017 Dec; 22(6):1026-1033. PubMed ID: 28748356
[TBL] [Abstract][Full Text] [Related]
20. Apoptin-derived peptide reverses cisplatin resistance in gastric cancer through the PI3K-AKT signaling pathway.
Zhou D; Liu W; Liang S; Sun B; Liu A; Cui Z; Han X; Yuan L
Cancer Med; 2018 Apr; 7(4):1369-1383. PubMed ID: 29522284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]